首页> 外文期刊>Journal of the American Society of Hypertension : >Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination
【24h】

Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination

机译:动态24小时心脏耗氧量和血压-心率变异性:奈必洛尔和缬沙坦单独或联合使用的影响

获取原文
获取原文并翻译 | 示例
           

摘要

We compared an angiotensin receptor blocker (valsartan; VAL), a beta blocker (nebivolol; NEB) and the combination of NEB/VAL with respect to 24 hour myocardial oxygen consumption (determined by 24 hour ambulatory heart rate-central systolic pressure product [ACRPP]) and its components. Subjects with hypertension (systolic blood pressure >140 or diastolic blood pressure >90; n = 26) were studied in a double blinded, double-dummy, forced titration, crossover design with 3 random-order experimental periods: VAL 320 mg, NEB 40 mg, and NEB/VAL 320/40 mg daily. After 4 weeks of each drug, ambulatory pulse wave analysis (MobilOGraph) was performed every 20 minutes for 24 hours. All three treatments resulted in nearly identical brachial and central systolic blood pressures. NEB alone or in combination with VAL resulted in lower ACRPP (by 11%-14%; P < .001 each) and heart rate (by 18%-20%; P < .001 each) compared with VAL, but stroke work (ACRPP per beat) was lower with VAL. Relative and adjusted variability (standard deviation and coefficient of variation) of heart rate were also lower with NEB and NEB/VAL than VAL. Results in African Americans, the majority sub-population, were similar to those of the entire treatment group. We conclude that the rate slowing effects of NEB cause ambulatory cardiac myocardial oxygen consumption to be lower with NEB monotherapy or NEB/VAL combination therapy than with VAL monotherapy. NEB/VAL is not superior to NEB alone in controlling heart rate, blood pressure, or ACRPP. Heart rate variability but not ACRPP variability is reduced by NEB or the combination NEB/VAL. There is no attenuation of beta blocker induced rate slowing effects of in African Americans. (C) 2015 American Society Of Hypertension. All rights reserved.
机译:我们比较了血管紧张素受体阻滞剂(缬沙坦; VAL),β阻滞剂(奈必洛尔; NEB)和NEB / VAL的组合对24小时心肌耗氧量的影响(由24小时动态心率-收缩压乘积[ACRPP确定])及其组件。在双盲,双模拟,强制滴定,交叉设计和3个随机实验期间,研究了高血压(收缩压> 140或舒张压> 90; n = 26)的受试者。毫克,每天NEB / VAL 320/40毫克。每种药物治疗4周后,每20分钟进行一次动态脉搏波分析(MobilOGraph),持续24小时。这三种治疗均导致肱动脉和中央收缩压几乎相同。与VAL相比,单独使用NEB或与VAL结合使用可降低ACRPP(降低11%-14%;每个P <.001)和心率(降低18%-20%; P <.001),但卒中工作( VAL降低了每搏的ACRPP。 NEB和NEB / VAL的相对和调整后心率变异性(标准差和变异系数)也低于VAL。非裔美国人(大多数亚人群)的结果与整个治疗组的结果相似。我们得出的结论是,NEB单药或NEB / VAL联合疗法使NEB的速度减慢效应导致动态心脏心肌耗氧量比VAL单药更低。 NEB / VAL在控制心率,血压或ACRPP方面并不优于单独的NEB。 NEB或NEB / VAL组合可降低心率变异性,但不能降低ACRPP变异性。在非裔美国人中,β受体阻滞剂诱导的速率减慢作用没有减弱。 (C)2015年美国高血压学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号